AKT1 and cancer: Recent studies have confirmed that CCND1, CDK4, and BCL2L1 are the key genes related to anticancer activity and targeted by brevilin A, whereas signaling pathways such as PI3K-Akt-mTOR, JAK-STAT, and MAPK may be part of Brevilin A’s activity on cancer cells.